Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490194 | 1.00 | ALOX15 (0.53) | ALOX15ALOX12TSHRPTGS2KDM4E | |
| SCHEMBL17662432 | 0.89 | ALOX15 (0.50) | ALOX15ALOX12TSHRPTGS2NPC1 | |
| SCHEMBL31009079 | 0.85 | ALOX15 (0.55) | ALOX15ALOX12TSHRPTGS2ALDH1A1 | |
| SCHEMBL25084169 | 0.85 | ALOX15 (0.55) | ALOX15ALOX12TSHRPTGS2ALDH1A1 | |
| SCHEMBL9589157 | 0.83 | ALOX15 (0.50) | ALOX15ALOX12TSHRPTGS2ALOX5 | |
| SCHEMBL25446354 | 0.83 | KDM4E (0.44) | ALOX15ALOX12PTGS2KDM4EALDH1A1 | |
| SCHEMBL22657669 | 0.81 | CTNNB1 (0.43) | PTGS2KDM4EALDH1A1ALOX5GAA | |
| SCHEMBL11888425 | 0.81 | TAAR1 (0.53) | ALOX15ALOX12TSHRKDM4EALDH1A1 | |
| SCHEMBL9588857 | 0.80 | ALOX15 (0.48) | ALOX15ALOX12TSHRALDH1A1NPC1 | |
| SCHEMBL5346679 | 0.80 | ALOX15 (0.48) | ALOX15ALOX12TSHRNPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019171088-A1 | BIOISPIRED PROTEASOME ACTIVATORS WITH ANTIAGEING ACTIVITY | NATIONAL HELLENIC RESEARCH FOUNDATION (GR) | 2019-09-12 | — | — | WO | disclosed |
| EP-2666761-A1 | HYDROXYTYROSOL ETHERS | Fundacio Imim (ES) | 2013-11-27 | — | — | EP | disclosed |
| US-20130267588-A1 | HYDROXYTYROSOL ETHERS | FUNDACIO IMIM (ES) | 2013-10-10 | — | — | US | disclosed |
| US-20130267588-A1 | HYDROXYTYROSOL ETHERS | FUNDACIO IMIM (ES) | 2013-10-10 | — | — | US | disclosed |
| US-20130267588-A1 | HYDROXYTYROSOL ETHERS | FUNDACIO IMIM (ES) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080555-A1 | HYDROXYTYROSOL ETHERS | FUNDACIÓ IMIM (ES) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012006783-A1 | PROCESS FOR PRODUCTION OF HYDROXYTYROSOL USING ORGANOMETALLIC COMPOUNDS | LONZA LTD (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-5475024-A | Useful in treating liver disease | EISAI CO., LTD. (JP) | 1995-12-12 | — | — | US | disclosed |
| US-5292901-A | Benzodioxole derivatives | EISAI CO., LTD. (JP) | 1994-03-08 | — | — | US | disclosed |
| EP-0281098-B1 | BENZODIOXOLE DERIVATIVES, COMPOSITIONS COMPRISING THE SAME, AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICAMENTS | Eisai Co., Ltd. (JP) | 1992-11-25 | — | — | EP | disclosed |
| US-5110956-A | Liver disorders | EISAI CO., LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| EP-0281098-A1 | Benzodioxole derivatives, compositions comprising the same, and the use of the same for the manufacture of medicaments | Eisai Co., Ltd. (JP) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267588-A1 | HYDROXYTYROSOL ETHERS | CNR1, CNR2, HCRTR1 | ALOX15 92/4885ALOX12 87/4885TSHR 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.